register

News & Trends - Pharmaceuticals

Lilly’s $960M deal in immunological and neurodegenerative diseases

Health Industry Hub | February 22, 2021 |

Pharma News: Eli Lilly and Rigel Pharmaceuticals announced a global exclusive license agreement and strategic collaboration to co-develop and commercialise a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases.

Pursuant to the collaboration, Lilly will also lead all clinical development of brain penetrating RIPK1 inhibitors in central nervous system (CNS) diseases.

Rigel’s lead RIPK1 inhibitor, R552, will begin Phase 2 clinical trials in 2021 as part of the collaboration. Rigel also has ongoing pre-clinical activities with its lead CNS penetrant RIPK1 inhibitor candidates.

“At Lilly, our immunology strategy is focused on the pursuit of novel targets that have the potential to develop into best-in-class medicines for patients with autoimmune conditions,” said Ajay Nirula, M.D., Ph.D., vice president of immunology at Lilly. “RIPK1 inhibitors are a promising approach, and R552 is an exciting addition to our immunology pipeline. We look forward to working with Rigel to advance its clinical development.”

“We are very excited to form this strategic partnership with Lilly. This collaboration will provide significant resources and expertise to support a broad investigation in multiple disease indications with our RIPK1 inhibitors,” said Raul Rodriguez, Rigel’s president and CEO. “With Lilly’s extensive knowledge in immune and CNS diseases, they are our ideal partner to ensure the clinical and commercial success of our RIPK1 inhibitor program.”

Under the terms of the agreement, Lilly will pay an upfront cash payment to Rigel of $125 million. Rigel may also be eligible to receive up to $835 million in potential development, regulatory, and commercial milestone payments.

Last year, Sanofi and Denali dropped their lead RIPK1 candidate SAR 443060 on toxicity issues that forced them to go back and focus on a follow-up compound.

In 2019, GlaxoSmithKline abandoned a RIPK1 drug it had been hoping to pair with checkpoint inhibitors in oncology, GSK3145095, after it failed a pancreatic cancer study.

GSK’s other clinical-stage RIPK1 inhibitor GSK2982772, aimed at inflammatory diseases, is listed as being in phase 1 for psoriasis in the company’s latest pipeline update.

Another organisation with an RIPK1 inhibitor nearing clinical development is Australia’s GenFleet Therapeutics, which is due to start phase 1 trials of its GFH312 candidate in March 2021.


News & Trends - Pharmaceuticals

Clinical and Laboratory Haematologist and Lead of the Molecular Haematology Service

Clinicians call for closer monitoring of patients post CAR T therapy

Health Industry Hub | February 17, 2025 |

Australian clinicians are raising questions about whether cancer patients need closer monitoring after receiving CAR T-cell therapy. A Peter MacCallum […]

More


News & Trends - MedTech & Diagnostics

Next-gen surgical mesh to fill critical gap after ban

Next-gen surgical mesh to fill critical gap after regulatory ban

Health Industry Hub | February 17, 2025 |

Next-generation urogynaecological surgical mesh implants are on the horizon for women suffering from pelvic organ prolapse (POP). This development aims […]

More


News & Trends - Pharmaceuticals

Contraceptive lawsuit against Bayer fails

Contraceptive lawsuit against Bayer fails

Health Industry Hub | February 17, 2025 |

The Victorian Supreme Court has dismissed a class action against Bayer for an allegedly defective contraceptive device. Justice Andrew Keogh […]

More


News & Trends - Pharmaceuticals

NSW Government ignored warnings since 2018: Mental health system unravels as psychiatrists quit en masse

NSW Government ignored warnings since 2018: Mental health system unravels as psychiatrists quit en masse

Health Industry Hub | February 17, 2025 |

The New South Wales Labor government’s plan to “redesign” the state’s mental health system, while excluding psychiatrists, has sparked intense […]

More


This content is copyright protected. Please subscribe to gain access.